DIVISION OF CARDIOLOGY - summary OF WEEKLY ROUNDS SCHEDULE

MONDAY, NOVEMBER 9 to FRIDAY, NOVEMBER 13, 2015

Monday, November 9:

8:00-9:00 / Aud B UH &
B2-116 VH
OTN Event #
49824958 / Cardiovascular Grand Rounds Presenter: D. Exner
Title of Presentation: Risk Evaluation after Myocardial Infarction – Are We Doing Enough?
Learning Objectives:
1. Review the most common modes of death after MI.
2. Appreciate the pros and cons of present risk assessment strategies.
3. Discuss new approaches to identify patients at risk.
12:00-1:30 / B6-115 UH
OTN Event #
39269164 / Adult Congenital Cardiac Surgery Rounds - Videoconference from Toronto
Cases & Learning Objectives:
Case 1 – Dr. Colman Dx: Repaired truncus arteriosus type II. Asyptomatic severe conduit stenosis. To review echo and MRI. Interventional referral.
Case 2 – Dr. Wald Dx: Unrepaired coarctation of aorta. Significant narrowing in the proximal descending aorta. Asymptomatic. To review cath, echo, MRI, and EST. Interventional referral.
Case 3 – Dr. Roche Dx: TOF PA. Severe PR. To review cath. Interventional referral.
Case 4 – Dr. Bergin Dx: Dextrocardia/L-TGA. Previous ASD suture repair. Asymptomatic. Mod-severe LAVV regurg and decrease systemic right ventricular. To review echo, MRI, and CP study. Surgical referral.
Case 5 – Dr. Wald Dx: Coarctation + bicuspid aortic valve and severe AI. To review echo, MRI, CT scan, ETT and CP study. Surgical referral.

Tuesday, November 10:

7:00-8:00 / B6-115 UH
OTN Event #
47648581 / Complex Revascularization Rounds Presenters: CV Surgeons & Interventional Cardiologists
Faculty Supervisors: D. Nagpal & P. Garg
Case-based presentation and discussion
Learning Objectives:
1. To develop a systematic approach to interpretation of coronary angiograms.
2. To discuss interesting case examples and their management.
3. To apply an evidence-based approach to complex revascularization cases in order to improve outcomes.
2:00-5:00 / B6-128 UH / DIDACTIC EDUCATION SESSIONS:
2:00-3:00 / B6-128 UH / Resynchronization therapy (CRT) for chronic CHF: Technique, mechanisms, evidence for efficacy Presenter: A. Huitema Faculty Supervisor: G. Jablonsky
Learning Objectives:
1. Discuss the technicalities of CRT implementation and therapy.
2. Review the mechanism of resynchronization.
3. Evaluate the guideline recommendations and therapeutic effectiveness of CRT.
3:00-4:00 / B6-128 UH / Invasive Rounds: Valves II – Mitral Regurgitation Presenter: S. Lavi

Wednesday, November 11:

8:00-9:00 / B6-115 UH / EP Rounds No rounds – Remembrance Day
12:00-1:00 / B6-115 UH &
C2-504 VH / Adult Congenital Cardiac Teaching Rounds -Videoconference from Toronto
No Rounds – Remembrance Day

Thursday, November 12:

8:00-9:00 / B6-128 UH / Graphics Rounds: STEMI Presenter: J. Brown
5:30 pm / The River Room – Museum London, 421 Ridout Street North, London.
519-850-2287
Sponsor:
Gregory Herriman, Servier Canada Inc. / Journal Club Attendance open to Residents, Fellows and Division Members. RSVP to Charlene Grass (ext. 33830 or email )
Presenter: B. Al-Sabeq Faculty Supervisor: P. Diamantouros
Paper for Presentation: Anticoagulant vs antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. D.M. Kent, I.J. Dahabreh, et al. European Heart Journal (2015) 36.2381-2389.
Learning Objectives:
1. Briefly review previous trials of medical therapy vs mechanical closure in cryptogenic stroke patients found to have a patent foramen ovale (PFO).
2. Review the recent meta-analysis comparing medical therapy strategies in cryptogenic stroke patients with PFOs.
3. Critically appraise the above meta-analysis.

Friday, November 13:

8:00-9:00 / B6-128 UH / EP Tracing Rounds: Case Presentations with ECG and Intra-cardiac tracings
Presenters: Attendings Fellows
Learning Objectives:
1. To develop a systematic approach to EP tracings.
2. To discuss interesting case examples.
3. To review electrophysiology principles and concepts.

Some of these educational activities/rounds are an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the Division of Cardiology Education Committee - Western University.

Supported by unrestricted grants-in-aid provided by:

AstraZeneca Canada (Crestor®, Brilinta (Ticagrelor)), Bayer HealthCare (XARELTO®rivaroxaban tablet), Boehringer Ingelheim (Canada) Ltd. Pradax (Dabigatran), Twynsta (telmisartan/amlodipine)), Bristol-Myers Squibb Canada & Pfizer Canada Inc., (Eliquis (apixaban)), Medtronic Canada Ltd., Merck (Ezetrol, Olmetec®), Servier Canada Inc. (Coversyl).